Brief: Medigene H1 EBITDA Loss Of EUR 13.2 Mln

Medigene AG

07/08/2019 06:41

Aug 7 (Reuters) - MEDIGENE AG  MDG1k.DE :
    * H1 REVENUE FROM CORE IMMUNOTHERAPIES BUSINESS GREW BY 47%
TO EUR
4.9 MILLION (6M-2018: EUR 3.4 MILLION)
    * H1 TOTAL REVENUE INCREASED BY 33% TO EUR 5.6
MILLION(6M-2018:
EUR4,253K).
    * H1 RESEARCH AND DEVELOPMENT EXPENSES INCREASED AS PLANNED
BY 26%
TO EUR 10.9 MILLION (6M-2018: EUR 8.7 MILLION)
    * H1 EBITDA LOSS INCREASED BY 77% TO EUR 13.2
MILLION(6M-2018: EUR
7.5 MILLION)
    * CONFIRMED FINANCIAL GUIDANCE ISSUED IN 3M-2019 QUARTERLY
REPORT

Source text for Eikon:  ID:nPexZYMsWa 
Further company coverage:  MDG1k.DE 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))